A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Senior Director Pathology

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA$323k - $437k

About the Job

Requirements

  • The ideal candidate will have 15 or more years of experience as a pathologist in biotechnology, pharmaceuticals, or at a contract research organization.
  • A veterinary degree and ACVP or ECVP board certification in clinical pathology are required; a PhD is preferred but not required in lieu of relevant pathology experience.
  • Demonstrated scientific curiosity and aptitude through a scientific publication and/or presentation record.
  • Strong interest in areas of the company’s research emphasis; demonstrated experience in these areas is preferred.
  • Strong communication skills.
  • Ability and interest to travel for essential company activities.

Responsibilities

  • Provide scientific leadership for the interpretation and application of clinical pathology data across the research and development portfolio.
  • Assess clinical pathology of preclinical results for platform and program support.
  • Review non-GLP and GLP study clinical pathology data.
  • Interpret and report findings and their significance to program teams and broader audiences through descriptions, data tables, and scientific presentations.
  • Contribute clinical pathology reports and/or reviews for regulatory filings.
  • Consult with internal and external stakeholders on preclinical study design and interpretation.
  • Actively participate in program and platform meetings.
  • Mentor the clinical pathology scientist and collaborate with pathology team members to assure optimal support of data generation and analysis in nonclinical studies.
  • Share biomarker and translational expertise across Research and Early Development.
  • Participate in group, department, and company meetings and activities.

Desired Qualifications

  • A PhD is preferred but is not required in lieu of relevant pathology experience.
  • Demonstrated experience in areas of the company’s research emphasis is preferred.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs